Invivyd (NASDAQ:IVVD – Get Free Report) posted its earnings results on Monday. The company reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.03, FiscalAI reports. The business had revenue of $15.45 million for the quarter, compared to analysts’ expectations of $15.04 million. Invivyd had a negative net margin of 183.90% and a negative return on equity of 59.73%.
Invivyd Price Performance
NASDAQ IVVD opened at $0.58 on Monday. Invivyd has a 12 month low of $0.53 and a 12 month high of $3.07. The company has a market capitalization of $171.58 million, a price-to-earnings ratio of -1.76 and a beta of 1.20. The company’s fifty day moving average price is $0.72 and its two-hundred day moving average price is $1.09.
Analyst Ratings Changes
A number of brokerages have commented on IVVD. HC Wainwright reiterated a “buy” rating on shares of Invivyd in a report on Tuesday, September 29th. Cantor Fitzgerald restated an “overweight” rating on shares of Invivyd in a research note on Thursday, August 27th. Weiss Ratings raised Invivyd from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, September 8th. Finally, BTIG Research restated a “buy” rating on shares of Invivyd in a research note on Monday, September 14th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $10.00.
Read Our Latest Stock Report on Invivyd
Insiders Place Their Bets
In other news, insider Jill Andersen sold 30,706 shares of the business’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $0.84, for a total value of $25,793.04. Following the completion of the sale, the insider owned 283,774 shares of the company’s stock, valued at approximately $238,370.16. The trade was a 9.76% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders have sold 103,024 shares of company stock worth $86,540. 12.25% of the stock is owned by company insiders.
About Invivyd
Invivyd is a biotechnology company focused on developing antibody-based medicines to help prevent and treat infectious diseases, with an emphasis on COVID-19. Its work includes discovering and engineering monoclonal antibodies intended to retain activity against changing viral variants. The company’s lead product, pemivibart, is marketed in the United States as PEMGARDA. The U.S. Food and Drug Administration authorized it for emergency use as pre-exposure prevention of COVID-19 in certain people with moderate-to-severe immune compromise who may not have an adequate response to vaccination.
Read More
- Five stocks we like better than Invivyd
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
Receive News & Ratings for Invivyd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invivyd and related companies with MarketBeat.com's FREE daily email newsletter.
